SCHEMBL7520323

SCHEMBL7520323

CC(=O)Oc1ccc(C(=O)C=Cc2ccccc2)c([N+](=O)[O-])c1OC(C)=O.O=C(C=Cc1ccc(O)c(O)c1[N+](=O)[O-])c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.44
CCR6 P51684 1/20 0.44
DBH P09172 1/20 0.42
MAOB P27338 4/20 0.41
CYP1B1 Q16678 3/20 0.41
BCHE P06276 2/20 0.41
MAPT P10636 8/20 0.41
RAB9A P51151 5/20 0.41
LMNA P02545 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
NPC1 O15118 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 3/20 0.38
PLIN1 O60240 1/20 0.38
TNFRSF1A P19438 1/20 0.38
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27575919 0.86 HSP90AA1 (0.56) HSP90AA1CCR6MAOBCYP1B1BCHE
SCHEMBL7432840 0.79 MAOB (0.59) DBHMAOBCYP1B1BCHEMAPT
SCHEMBL7432841 0.77 MAPT (0.55) HSP90AA1DBHMAOBCYP1B1BCHE
SCHEMBL6036504 0.69 DBH (0.59) HSP90AA1CCR6DBHMAOBCYP1B1
SCHEMBL7426634 0.69 MAPT (0.41) HSP90AA1CCR6MAPTRAB9ALMNA
SCHEMBL7426625 0.69 MAPT (0.41) HSP90AA1CCR6MAPTRAB9ALMNA
SCHEMBL6036507 0.69 DBH (0.59) HSP90AA1CCR6DBHMAOBCYP1B1
SCHEMBL28208626 0.66 MAPT (0.51) MAPTLMNAMEN1KMT2AALDH1A1
Chalcone SCHEMBL30749166 0.66 CYP1B1 (0.76) DBHMAOBCYP1B1BCHEMAPT
SCHEMBL7513057 0.66 PTPN1 (0.43) MAPTRAB9ALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US claimed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 HSP90AA1 2624/4885CCR6 3101/4885DBH 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.